• Valentín García-Gutiérrez, Antonio Jiménez-Velasco, M Teresa Gómez-Casares, Fermín Sánchez-Guijo, Jose Luis López-Sendón, and Juan Luis Steegmann Olmedillas.
• Servicio de Hematología, Hospital Universitario Ramón y Cajal, Madrid, España. Electronic address: jvalentingg@gmail.com.
• Med Clin (Barc). 2016 Jun 17; 146 (12): 561.e1-8.

Introduction And ObjectivesThe second generation tyrosine kinase inhibitors (TKI, dasatinib and nilotinib) used in chronic myeloid leukemia (CML) treatment have shown a benefit compared to imatinib in responses achieved and disease progression. However, both have been related to some cardiovascular toxicity, being more frequent in patients with cardiovascular risk factors (CVRFs). Nowadays, due to the lack of recommendations for CML patients, CVRF management is carried out heterogeneously. The aim of this work is to develop recommendations on the prevention and monitoring of cardiovascular events (CVD) in patients with CML treated with TKIs.Material And MethodsExperts from the Spanish Group of Chronic Myeloid Leukemia together with experts in cardiovascular risk have elaborated, after a consensus meeting, recommendations for the prevention and follow-up of CVE in patients with CML treated with TKI.ResultsRecommendations regarding the necessary information to be collected on clinical history, treatment decisions, as well as treatment and monitoring of CVRFs are shown in this document.ConclusionsTKI treatment requires comprehensive patient management from a multidisciplinary approach, in which both the prevention and management of CVRFs are essential.Copyright © 2016 Elsevier España, S.L.U. All rights reserved.

28 keywords...

hide…